Viewing Study NCT05474261


Ignite Creation Date: 2025-12-24 @ 11:58 AM
Ignite Modification Date: 2025-12-27 @ 4:51 PM
Study NCT ID: NCT05474261
Status: COMPLETED
Last Update Posted: 2022-07-29
First Post: 2022-07-19
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Valsalva Maneuver in Thyroidectomy
Sponsor: University of Foggia
Organization:

Study Overview

Official Title: Clinical Usefulness of the Valsalva Maneuver to Improve Hemostasis During Thyroidectomy
Status: COMPLETED
Status Verified Date: 2022-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Bleeding after total thyroidectomy remains a rare event that affects early postoperative morbidity, occurring in 0.3% up to 4.2% of cases. Intraoperative bleeding is an unpleasant complication, and it is often easily manageable though postoperative bleeding may represent a life-threatening condition for the patient.

Between January 2019 to February 2022 , 250 consecutive patients were listed for thyroidectomy. The Investigators selected 178 patients and divided them in two groups based on the execution of the Valsalva Manoeuvre.

The purpose of the investigator is to clarify whether the routine intraoperative execution of a Valsalva manoeuvre (VM) may affect the detection of bleeding that would otherwise remain occult and therefore may manifest in the postoperative period.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: